Stocks to Watch: CVS Health, PepsiCo, Repare Therapeutics

By Connor Hart

CVS Health is conducting a strategic review of options for the company, including a possible breakup of the industry giant, according to people with knowledge of the matter. News of the ongoing review comes after The Wall Street Journal on Monday morning reported that Glenview Capital Management, a major hedge-fund investor, would meet with top executives of the healthcare company to propose ways to improve its operations. Shares, which ended the regular session up 2.4% at $62.88, rise 2.7%, to $64.59, in after-hours trading.

PepsiCo is in advanced talks to acquire Siete Foods for more than $1 billion, The Wall Street Journal reported, citing people familiar with the matter. A deal could be announced soon, provided the talks don't fall apart, the people said. Texas-based Siete is known for its Mexican-inspired products including tortilla chips, soft tortillas, jarred enchilada mix and dairy-free queso dip.

Repare Therapeutics said it received encouraging early phase 1 data for its camonsertib inhibitor combined with palliative radiation for the treatment of metastatic tumors harboring an ataxia-telangiectasia-mutated mutation. Camonsertib is an orally active, selective ataxia-telangiectasia kinase inhibitor. Ataxia-telangiectasia kinase is an inherited disorder that affects the nervous system, immune system, and other body systems. Shares fall 3.8%, to $3.31, in after-hours trading.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

September 30, 2024 19:52 ET (23:52 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.